Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

View Full Paper
Ask AI
Bookmark
Share

Authors

LZLiyun ZhaoGBGuanchen BaiYBYanliang Bai

Discussion

Loading...

Member takes

Overview

This trial shows an overall response rate of 78.3% in newly diagnosed TP53-mutant AML patients, implying that DEC3-VEN induction therapy is promising.

Key Points

  • 78.3% overall response rate in newly diagnosed patients indicates a strong therapeutic effect.
  • Median overall survival was reported at 8 months with notable effectiveness observed during induction therapy.
  • Induction therapy using Venetoclax with multi-frequency Decitabine demonstrated significant safety and efficacy.
  • Findings suggest potential for broader applications in TP53-mutant leukemia treatment, highlighting need for further research.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da54https://doi.org/10.1182/blood-2025-3395
View Full Paper
Ask AI
Bookmark
Share